Vilobelimab

Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc[1].

Product Specifications

CAS Number

[2250440-41-4]

Product Name Alternative

CaCP-29, IFX-1

UNSPSC

12352203

Target

Complement System; SARS-CoV

Type

Inhibitory Antibodies

Related Pathways

Anti-infection; Immunology/Inflammation

Applications

COVID-19-anti-virus

Field of Research

Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/vilobelimab.html

Purity

99.95

Solubility

10 mM in DMSO

Smiles

[Vilobelimab]

Molecular Weight

(145.88 kDa)

References & Citations

[1]Michael Bauer, et al. Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study) . Crit Care Explor. 2021 Nov 17;3 (11) :e0577.